Effects of probiotics or broccoli supplementation on Helicobacter pylori eradication with standard clarithromycin-based triple therapy
| Autor: | Shin Ju Oh, Jun-Hyung Cho, Jae Young Jang, Chi Hyuk Oh, Jung-Wook Kim, Yoo Min Park, Young Woon Chang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Chronic gastritis sulforaphane Brassica Gastroenterology Helicobacter Infections 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Clarithromycin Republic of Korea medicine Humans Broccoli sprout extract Adverse effect biology business.industry Amoxicillin Proton Pump Inhibitors Helicobacter pylori biology.organism_classification medicine.disease Anti-Bacterial Agents chemistry probiotics helicobacter pylori Medicine 030211 gastroenterology & hepatology Drug Therapy Combination Original Article business medicine.drug Saccharomyces boulardii Sulforaphane |
| Zdroj: | The Korean Journal of Internal Medicine, Vol 35, Iss 3, Pp 574-581 (2020) The Korean Journal of Internal Medicine |
| ISSN: | 2005-6648 1226-3303 |
| Popis: | Background/aims The eradication failure rate of standard triple therapy (proton pump inhibitor, clarithromycin, and amoxicillin) for Helicobacter pylori infection has increased owing to antibiotic resistance in Korea. We assessed whether Saccharomyces boulardii probiotic or broccoli sprout extract sulforaphane supplementation could increase the H. pylori eradication rate and/or reduce antibiotic-associated adverse events. Methods A total of 217 patients with H. pylori-positive chronic gastritis or peptic ulcer disease were recruited. Clarithromycin resistance was assessed in all patients by testing for A2142G and A2143G point mutations in H. pylori 23S rRNA using a dual-priming polymerase chain reaction (PCR) oligonucleotide. Thirty-four patients (17.3%) were clarithromycin-resistant and were excluded from the study. Finally, 183 patients with infections not resistant to clarithromycin were randomly assigned to triple therapy only (group A, n = 61), triple therapy plus probiotics (group B, n = 61), or triple therapy plus sulforaphane (group C, n = 61) groups. CYP2C19 polymorphisms were examined at position G681A of exon 5 and G636A of exon 4 by PCR with restriction fragment length polymorphism (PCR-RFLP) analysis. H. pylori eradication was assessed by 13C-urea breath test 4 weeks after treatment completion. Results The eradication rates were similar among the groups both in the intention- to-treat (A = 85.2%, B = 89.6%, and C = 81.6%) and per-protocol (A = 89.2%, B = 86.8%, and C = 96.3%) analyses. The frequencies of overall adverse events in the groups also did not differ (A vs. B: p = 0.574; A vs. C: p = 1.000). Conclusion Probiotic or sulforaphane with triple therapy for H. pylori infection neither increased the eradication rate nor reduced the occurrence of adverse events. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|